Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 5, 2004, Pages 285-292

  Rochdi, M ^a   Gonzalez M A ^b   Dirksen, Sharon J Hirshey ^c  

^a ICON Development Solutions   (United States)

^b P Kinetics International Inc   (United States)

^c Celltech Americas Inc   (United States)

Author keywords

ADHD; Dose proportionality; Metadate CD; Methylphenidate HCl

Indexed keywords

EQUASYM XL; METHYLPHENIDATE;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; ATTENTION DEFICIT DISORDER; BIOEQUIVALENCE; CALCULATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIET RESTRICTION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENDER; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 2542490282     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42285     Document Type: Article

References (18)

1. Dulcan M 1990 Using psychostimulants to treat behavior disorders of children and adolescents. J Child Adolesc Psychopharmacol 1: 7-20
2. Elia J, Ambrosini PL, Rapoport JL 1999 Treatment of attention deficit hyperactivity disorder. N Engl J Med 340: 780-788
3. Fitzpatrick PA, Klorman R, Brumaghim JT, Borgsted AD 1992 Effects of sustained-release and standard preparations of methylphenidate on attention deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 31: 226-234
4. Gibaldi M, Perrier D 1982 Pharmacokinetics, Second Edition Revised and Expanded. Marcel Dekker, Inc., New York, USA
5. Gonzalez M, Pentikis H, Anderl N, Benedict M, DeCory H, Dirksen S 2002 Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40: 175-184
6. Greenhill LL 1998 Childhood attention deficit hyperactivity disorder: pharmacological treatments. In: Nathan PE, Gorman J (eds) Treatments That Work. Saunders, Philadelphia, pp 42-64
7. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S 2002a Practice parameter for the use of stimulant medications in the treatment of children, adolescents and adults. J Am Acad Child Adolesc Psychiatry 41 (2 Suppl): 26S-49S
8. Greenhill LL, Findling RL, Swanson JM and the MPH MR ADHD Study Group 2002b A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 109: 1-7
9. Kimko HC, Cross JT, Abernethy DR 1999 Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 37: 457-470
10. National Institute of Health 2000 National Institutes of Health consensus development conference statement: diagnosis and treatment of attention deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatric 39: 192-193
11. Patrick K, Markowitz J 1997 Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum Psychopharmacol 12: 527-546
12. Pelham WE, Sturges J, Hoza J, Schmidt C, Bijlsma JJ, Militch R, Moorer S 1987 Sustained-release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit hyperactivity disorder. Pediatrics 80: 491-501
13. Pelham WE, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE 1990 Relative efficacy of long-acting stimulants on children with attention deficit hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 86: 226-237
14. Pentikis H, Simmons RD, Benedict M, Hatch SJ 2002 Methylphenidate bioavailability in adults following an extended-release multiparticulate formulation administered sprinkled or as an intact capsule. J Am Acad Child Adolesc Psychiatry 41: 443-449
15. Swanson JM, Kinsbourne M, Roberts W, Zucker K 1978 Time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity. Pediatrics 61: 21-29
16. Swanson JM, Volkow ND 2002 Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. Behav Brain Res 130: 73-78
17. Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, De Cory HH, Dirksen SJH, Hatch SJ and the COMACS Study Group 2004 A comparison of once-daily extended-release methylphenidate formulations in children with ADHD in the laboratory school. Pediatrics 113: e206-e216.
18. Wigal SB, Sanchez D, DeCory HH, D'Imperio J, Swanson JJ 2003 Selection of the optimal dose ratio for a controlled-delivery formulation of methylphenidate. J Appl Res 3: 46-63